Biotech Values

[DewDiligence]

Re: Sole vs multiple Lovenox approvals

>MNTA – one of the interesting questions remaining open is whether FDA has provided parallel guidance to Teva and/or Amphastar.<

From Teva, we can expect a no comment unless/until they have positive Lovenox news; hence, no news from Teva ought to be good news for MNTA shareholders.

For Amphastar, we have to rely on WPI to disseminate news. Any correspondence from the FDA on Lovenox is arguably a material event for WPI, so there’s a decent chance we’ll learn at least the rudiments of what is going on.